Press Releases

Date Title and Summary View
Toggle Summary MediWound Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Submitted Biological License Application to the FDA for NexoBrid  EscharEx U.S. Phase 2 Study Resumed Patient Screening YAVNE, Israel , Aug. 06, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to
View HTML
Toggle Summary MediWound to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020
YAVNE, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the second
View HTML
Toggle Summary MediWound Announces Submission of Biologics License Application to the U.S. FDA for NexoBrid for the Treatment of Severe Thermal Burns
YAVNE, Israel , June 30, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in severe burn and wound management, today announced it has submitted a Biologics License Application (BLA) to
View HTML
Toggle Summary MediWound Reports First Quarter 2020 Financial Results and Provides Corporate Update
EscharEx U.S. Phase 2 Study Resumed Patient Screening YAVNE, Israel , May 20, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today
View HTML
Toggle Summary MediWound to Report First Quarter 2020 Financial Results and Host a Conference Call and Webcast on May 20, 2020
YAVNE, Israel, May 13, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the first
View HTML
Toggle Summary MediWound Strengthens its NexoBrid European Presence with Additional Distribution Agreements
YAVNE, Israel , May 04, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet medical needs in severe burn and wound management, today announced the expansion of its NexoBrid ® European presence with
View HTML
Toggle Summary MediWound Strengthens Board of Directors
Company Announces Appointments of Samuel Moed and David Fox Chairman Stephen T. Wills Named Executive Chairman YAVNE, Israel , April 27, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in
View HTML
Toggle Summary MediWound Provides Corporate Update Related to COVID-19 Pandemic
YAVNE, Israel , March 30, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today provided an update on certain impacts of the COVID-19
View HTML
Toggle Summary BARDA Upsizes its Contract with MediWound Awarding an Additional $5.5 Million for Emergency Readiness for NexoBrid Deployment
Total non-dilutive funds for NexoBrid now valued at over $200 million YAVNE, Israel , March 03, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today
View HTML
Toggle Summary MediWound to Present at Cowen and Company 40th Annual Healthcare Conference
YAVNE, Israel , Feb. 28, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Sharon Malka , MediWound’s Chief Executive Officer, will
View HTML